0000899243-21-029533.txt : 20210722
0000899243-21-029533.hdr.sgml : 20210722
20210722185349
ACCESSION NUMBER: 0000899243-21-029533
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210713
FILED AS OF DATE: 20210722
DATE AS OF CHANGE: 20210722
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DAWES KAREN A
CENTRAL INDEX KEY: 0001261506
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-14656
FILM NUMBER: 211108626
MAIL ADDRESS:
STREET 1: 579 BELLEVUE AVE
CITY: NEWPORT
STATE: RI
ZIP: 02840
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REPLIGEN CORP
CENTRAL INDEX KEY: 0000730272
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 042729386
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 41 SEYON STREET
STREET 2: BUILDING 1, SUITE 100
CITY: WALTHAM
STATE: MA
ZIP: 02453
BUSINESS PHONE: 7814499560
MAIL ADDRESS:
STREET 1: 41 SEYON STREET
STREET 2: BUILDING 1, SUITE 100
CITY: WALTHAM
STATE: MA
ZIP: 02453
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2021-07-13
2021-07-15
0
0000730272
REPLIGEN CORP
RGEN
0001261506
DAWES KAREN A
C/O REPLIGEN CORPORATION
41 SEYON ST., BLDG 1, STE 100
WALTHAM
MA
02453
1
0
0
0
Common Stock
2021-07-13
4
M
0
2929
41.19
A
118982
D
Common Stock
2021-07-13
4
S
0
441
201.27
D
118541
D
Common Stock
2021-07-13
4
S
0
630
202.29
D
117911
D
Common Stock
2021-07-13
4
S
0
444
203.09
D
117467
D
Common Stock
2021-07-13
4
S
0
5
204.02
D
117462
D
Stock Option (Right to Buy)
41.19
2021-07-13
4
M
0
2929
0.00
A
2025-07-21
Common Stock
2929
0
D
Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on June 8, 2021.
$201.27 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.77 to $201.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
$202.29 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.77 to $202.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
$203.09 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.86 to $203.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
$204.02 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.01 to $204.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
This option is fully vested and exercisable.
This Form 4/A amends a Form 4 filed on 7/15/2021 to correct the presentation of the stock sold to reflect the multiple transactions to sell the total 1,520 shares.
/s/ Kimberly Brown (Attorney in Fact)
2021-07-22